Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights
Loading...All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
Leukocyte immunoglobulin-like receptor B2(LILRB2, also known as ILT4) is a type I transmembrane inhibitory immune receptor encoded by LILRB2 gene, which is selectively expressed on the surface of monocytes, macrophages, dendritic cells and tumor-related myeloid inhibitory cells, with multiple immunoglobulin domains distributed extracellular and typical ITIM inhibitory motifs in cells, and is a key checkpoint molecule for regulating the immune activity of myeloid cells. Compared with other LILR family subtypes, LILRB2 has a broader ligand recognition spectrum, which can not only combine classical HLA-I molecules with HLA-G molecules, but also recognize ANGPTL family cytokines. By recruiting SHP-1/SHP-2 phosphatase, it can block NF-κB and promote the transcription cascade reaction, thus achieving a powerful immunosuppressive effect. In the physiological self-tolerance state of the body, the basic active LILRB2 signal can restrain the overactivation of myeloid cells, avoid the self-tissue damage induced by uncontrolled inflammatory response, and maintain the peripheral immune homeostasis. However, in the tumor microenvironment, sustained ligand binding can continuously activate LILRB2 signal, induce macrophages to polarize to immunosuppressive M2 phenotype, and inhibit the antigen cross-presentation ability of dendritic cells, which significantly weakens the anti-tumor immune response of CD8⁺ cytotoxic T cells. Other myeloid checkpoint molecules can't compensate the immunosuppressive function mediated by LILRB2 broad-spectrum ligand. Targeted blocking LILRB2 can effectively reshape the body's anti-tumor immunity and form a significant synergistic therapeutic effect with PD-1 inhibitors. Moreover, the high expression of LILRB2 is closely related to the metastasis of advanced solid tumors, which is the core and irreplaceable research target of immunotherapy screening at myeloid immune checkpoints.
LILRB2 is anchored on the lipid bilayer of myeloid immune cell membrane, which specifically plays the role of myeloid inhibitory receptor. By virtue of the folded structure of immunoglobulin arranged in series outside the cell, it can widely identify the body's own ligands and tumor-derived ligands, recruit phosphatase through intracellular signal transduction, and start the downstream immunosuppression cascade reaction. Its unique multi-ligand recognition ability is obviously different from that of single-target and narrow-spectrum inhibitory receptors, which constitutes the core regulatory axis of myeloid immunosuppression in tumor microenvironment. LILRB2-mediated ITIM signaling pathway can link the exposure level of tumor ligands with the status of myeloid immune paralysis, and dynamically regulate the balance between peripheral immune tolerance and anti-tumor immune monitoring according to the tumor load of the body. This molecule is widely involved in the physiological and pathological processes such as the construction of placental immune tolerance, the continuous progress of chronic inflammation and the immune escape of malignant tumors. The loss or targeted blocking of LILRB2 function can effectively relieve the immunosuppression of myeloid cells and reactivate the immunokilling activity of tumor-specific T cells. To sum up, LILRB2 is the key core target for the study of leukocyte checkpoint mechanism and the research and development of tumor combined immunotherapy.
Fig. 1 Full pathogenic signaling schematic for studying LILRB2-PI3K-AKT cascade function driving foam macrophage differentiation and MET release during atherosclerotic plaque development.1
The biological functions of multi-Ig LILRB2 inhibitory receptor are fully focused on HLA/ANGPTL ligand binding and myeloid immune suppression:
Creative Biolabs offers high-quality LILRB2 proteins through optimized myeloid cell expression systems, including full-length inhibitory receptor and isolated extracellular Ig ligand-binding domain variants. These products retain native HLA/ANGPTL dual binding activity, suitable for immune checkpoint blocking antibody screening assays. All LILRB2 proteins undergo strict quality control to ensure consistent performance and reliable application across immuno-oncology research platforms.
Not finding the membrane protein product you need? Contact us to start your one-stop custom service!
Creative Biolabs provides custom-engineered LILRB2 stable cell lines, including myeloid mimic overexpression and blank empty vector control models. These cell lines are optimized for inhibitory receptor profiling and macrophage polarization functional analysis. Each cell line undergoes stringent validation to ensure stable expression profiles during long-term immune cell co-culture, and can be widely deployed for checkpoint combination drug screening experiments.
Not finding the stable cell line product you need? Contact us to start your one-stop custom service!
High-specificity recombinant antibodies targeting LILRB2 are developed via advanced antibody engineering technologies, with no cross-reactivity with other LILR family inhibitory receptors. These antibodies are validated for macrophage and dendritic cell membrane localization detection and tumor stromal expression profiling, and can be combined with HLA-G detection reagents to analyze complete LILRB2 inhibitory complexes in tumor microenvironment cell models.
Not finding the recombinant antibody product you need? Contact us to start your one-stop custom service!
Beyond catalog products, Creative Biolabs offers specialized custom services for LILRB2 research:
LILRB2 (ILT4) is a myeloid inhibitory checkpoint binding HLA/ANGPTLs to suppress anti-tumor immune responses.
LILRB2 blockade relieves myeloid immune suppression, a promising combination target with PD-1 therapy.
No, all LILRB2 products and services are strictly for research use only, not intended for clinical diagnosis or human therapeutic trials.
Offerings include full-length LILRB2 inhibitory receptors, isoform-specific detection antibodies and custom stable cell lines for myeloid immunity research.
LILRB2 proteins are validated via HLA-G and ANGPTL dual ligand binding functional testing.
